Pasithea Therapeutics Receives Nasdaq Non-Compliance Notice

Summary

Pasithea Therapeutics Corporation received a notice from Nasdaq on June 23, 2025, about non-compliance with the $1 minimum bid price rule. The company has 180 days to regain compliance by having a closing bid price of $1 or higher for ten consecutive trading days. They are exploring options, including a potential reverse stock split. If compliance is not achieved, an additional 180-day period may be granted. This notice does not affect the company’s operations or SEC reporting requirements.Reuters

Impact Analysis

First-Order Effects: The notification from Nasdaq introduces a significant risk for Pasithea Therapeutics, as failure to comply could result in delisting from the exchange. This regulatory challenge could impact investor confidence and stock liquidity, potentially leading to a decline in stock price due to perceived instability.Reuters Second-Order Effects: Other companies in similar circumstances or the biotechnology sector may face increased scrutiny regarding their stock performance and regulatory compliance.Reuters Investment Opportunities: Investors might consider options strategies such as protective puts to mitigate potential losses or speculative positions anticipating compliance measures like a reverse stock split.Reuters